We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 04. 28. | 장 마감 후 (AMC) | $0.23 | — | — | $114.05M | — | 예정 |
| FY2026 Q1 | 2025. 03. 31. | 시각 미정 | — | $-0.19 | — | — | $84.69M | 보고됨 |
| FY2025 Q3 | 2024. 09. 30. | 시각 미정 | — | $-0.67 | — | — | $247.21M |
Consensus PT $25.8 · 5 analysts
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
| 보고됨 |
| FY2025 Q2 | 2024. 06. 30. | 시각 미정 | — | $-0.47 | — | — | $164.32M | 보고됨 |
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
| # | 기관 | 운용 형태 | 보유 주식 | 평가액 | 비중 | 변화율 | 포지션 |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 231,600 | $4.02B | 0.00% | — | 신규 편입 |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 89,300 | $1.68B | 0.00% | — | 신규 편입 |
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software. Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.
Stored first · Google News · Yahoo Finance (English)
U.S. Supreme Court rejects CareDx appeal in Natera false-advertising dispute - Reuters
U.S. Supreme Court rejects CareDx appeal in Natera false-advertising dispute Reuters
U.S. Supreme Court rejects CareDx appeal in Natera false-advertising dispute - TradingView
U.S. Supreme Court rejects CareDx appeal in Natera false-advertising dispute TradingView
CareDx (CDNA) Supreme Court Appeal Denied, Lower Court Ruling St - GuruFocus
CareDx (CDNA) Supreme Court Appeal Denied, Lower Court Ruling St GuruFocus
Justices Skip CareDx's Bid To Revive $45M False Ad Award - Law360
Justices Skip CareDx's Bid To Revive $45M False Ad Award Law360
CAREDX INC (NASDAQ:CDNA) Shows Perfect Minervini Trend Template and High Growth Momentum Setup - ChartMill
CAREDX INC (NASDAQ:CDNA) Shows Perfect Minervini Trend Template and High Growth Momentum Setup ChartMill
Analysts Offer Insights on Healthcare Companies: Fisher & Paykel Healthcare Corporation Limited (OtherFSPKF) and CareDx (CDNA) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Fisher & Paykel Healthcare Corporation Limited (OtherFSPKF) and CareDx (CDNA) The Globe and Mail